Evaluation of percutaneous mechanical thrombectomy via the AngioJet system combined with catheter-directed thrombolysis for the treatment of symptomatic lower extremity deep venous thrombosis.
Current methods of treating lower extremity deep venous thrombosis (LEDVT), such as catheter-directed thrombolysis (CDT) alone, or percutaneous mechanical thrombectomy (PMT) alone, are accompanied by unacceptably high risks of complications. This preliminary retrospective study evaluated the efficacy of CDT combined with PMT (via the AngioJet system), relative to CDT alone, in treating LEDVT. Forty-two patients (43 limbs) with symptomatic DVT received either CDT alone (n = 12), or PMT combined with CDT (PMT+CDT), from May 2012 to December 2016. The groups were compared for clinical outcomes, and demographics, LEDVT risk factors, and dosages of urokinase. Thrombus removal, by venographic evidence, was classified as grades I (<50%), II (50 to 99%), or III (>99%). In the CDT (PMT+CDT) cohorts, grades I, II, and III thrombus removal was achieved by 8% (3%), 17% (10%), and 75% (87%) of patients, respectively. The urokinase dosage and hospitalization required by the CDT group (5.29 ± 0.45 million IU, 20.4 ± 4.6 d) was significantly greater than that of the PMT+CDT (4.08 ± 1.15 million IU, 16.0 ± 6.0 d; P = 0.001, 0.039). The clinical outcomes of the two groups were similar. Combined PMT and CDT was effective and safe for LEDVT clinical therapy, and hospital stay, urokinase dosage, and complications were less compared with patients who received CDT only.